RxDoctor Payments Data

Katherine Wilson

Family · Abilene, TXNPI 1962702779

Payments from drug & device makers

$754in general payments, 2019–2025

Across 41 payments — averaging $18.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$157
  • Exact Sciences$109
  • AstraZeneca$101
  • Novo Nordisk$71
  • Boehringer Ingelheim$67
  • Otsuka America Pharmaceutical, Inc.$50
  • plus $199 from 9 others

What the payments were for

  • Food & beverage$754100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$754 in reported general payments places this provider in the 60th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$33,196
Medicare patients
152
Services billed
469

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept12$85,439
OzempicSemaglutide56$70,109
EliquisApixaban102$65,664
MounjaroTirzepatide46$51,569
JanuviaSitagliptin Phosphate54$44,983
Lagevrio (Eua)Molnupiravir38$37,195
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$31,137
Tresiba Flextouch U-200Insulin Degludec29$27,471
FarxigaDapagliflozin Propanediol19$21,337
Bydureon BciseExenatide Microspheres14$18,267
LinzessLinaclotide28$16,153
GemtesaVibegron25$15,927
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$13,479
XareltoRivaroxaban30$12,054
Tresiba Flextouch U-100Insulin Degludec18$9,066

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$71$70,10956 claims
PfizerEliquis$18$65,664102 claims
Lilly USA, LLCMounjaro$16$51,56946 claims
AstraZenecaFarxiga, Breztri Aerosphere$101$34,81633 claims
AbbVieLinzess$157$16,15328 claims
Johnson & JohnsonXarelto$21$12,05430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 15,456 family providers in Texas.

Other family in Abilene

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →